This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lanoteplase
- DrugBank Accession Number
- DB06245
- Background
Not Available
- Type
- Biotech
- Groups
- Investigational
- Biologic Classification
- Protein Based Therapies
Other protein based therapies - Protein Chemical Formula
- Not Available
- Protein Average Weight
- Not Available
- Sequences
- Not Available
- Synonyms
- Lanoteplase
- External IDs
- BMS-200980
- SUN 9216
- SUN-9216
Pharmacology
- Indication
Investigated for use/treatment in myocardial infarction.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Lanoteplase is a second generation derivative of alteplase, and a third generation recombinant plasminogen activator made from a deletion and point mutant of tissue type-plasminogen activator (t-PA). Lanoteplase has a longer half life than alteplase. Lanoteplase is a serine protease that binds to fibrin in a thrombus (blood clot)and cleaves the Arg-Val bond in plasminogen, producing active plasmin. Plasmin is an enzyme that degrades plasma proteins such as fibrin clots to clear blocked blood vessels that cause myocardial infarction (heart attack) or stroke.
Target Actions Organism UUrokinase plasminogen activator surface receptor Not Available Humans UFibrinogen alpha chain Not Available Humans UKallikrein-1 Not Available Humans ULaminin subunit alpha-5 Not Available Humans UCoagulation factor X Not Available Humans UFibronectin Not Available Humans UPlasminogen activator inhibitor 2 Not Available Humans UTetranectin Not Available Humans UKeratin, type II cytoskeletal 8 Not Available Humans UAnnexin A2 Not Available Humans ULaminin subunit beta-1 Not Available Humans ULaminin subunit gamma-1 Not Available Humans ULaminin subunit alpha-1 Not Available Humans UCalreticulin Not Available Humans UCalnexin Not Available Humans UProlow-density lipoprotein receptor-related protein 1 Not Available Humans ULaminin subunit alpha-3 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetylsalicylic acid The risk or severity of angioedema can be increased when Acetylsalicylic acid is combined with Lanoteplase. Alogliptin The risk or severity of angioedema can be increased when Alogliptin is combined with Lanoteplase. Alpha-1-proteinase inhibitor The therapeutic efficacy of Alpha-1-proteinase inhibitor can be decreased when used in combination with Lanoteplase. Alteplase The risk or severity of angioedema can be increased when Alteplase is combined with Lanoteplase. Aminocaproic acid The therapeutic efficacy of Aminocaproic acid can be decreased when used in combination with Lanoteplase. Anistreplase The risk or severity of angioedema can be increased when Anistreplase is combined with Lanoteplase. Aprotinin The therapeutic efficacy of Aprotinin can be decreased when used in combination with Lanoteplase. Azilsartan medoxomil The risk or severity of angioedema can be increased when Lanoteplase is combined with Azilsartan medoxomil. Benazepril The risk or severity of angioedema can be increased when Benazepril is combined with Lanoteplase. Captopril The risk or severity of angioedema can be increased when Captopril is combined with Lanoteplase. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- Not Available
- Kingdom
- Organic Compounds
- Super Class
- Organic Acids
- Class
- Carboxylic Acids and Derivatives
- Sub Class
- Amino Acids, Peptides, and Analogues
- Direct Parent
- Peptides
- Alternative Parents
- Not Available
- Substituents
- Not Available
- Molecular Framework
- Not Available
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 5U26HTF8RV
- CAS number
- 171870-23-8
References
- General References
- Zeymer U, Neuhaus KL: Lanoteplase: a viewpoint by Uwe Zeymer and Karl-Ludwig Neuhaus. BioDrugs. 2000 Mar;13(3):225-6. [Article]
- Bhana N, Spencer CM: Lanoteplase. BioDrugs. 2000 Mar;13(3):217-24. [Article]
- Nordt TK, Moser M, Kohler B, Kubler W, Bode C: Pharmacokinetics and pharmacodynamics of lanoteplase (n-PA). Thromb Haemost. 1999 Sep;82 Suppl 1:121-3. [Article]
- External Links
- Not Available
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Urokinase plasminogen activator receptor activity
- Specific Function
- Acts as a receptor for urokinase plasminogen activator. Plays a role in localizing and promoting plasmin formation. Mediates the proteolysis-independent signal transduction activation effects of U-...
- Gene Name
- PLAUR
- Uniprot ID
- Q03405
- Uniprot Name
- Urokinase plasminogen activator surface receptor
- Molecular Weight
- 36977.62 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural molecule activity
- Specific Function
- Cleaved by the protease thrombin to yield monomers which, together with fibrinogen beta (FGB) and fibrinogen gamma (FGG), polymerize to form an insoluble fibrin matrix. Fibrin has a major function ...
- Gene Name
- FGA
- Uniprot ID
- P02671
- Uniprot Name
- Fibrinogen alpha chain
- Molecular Weight
- 94972.455 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Glandular kallikreins cleave Met-Lys and Arg-Ser bonds in kininogen to release Lys-bradykinin.
- Gene Name
- KLK1
- Uniprot ID
- P06870
- Uniprot Name
- Kallikrein-1
- Molecular Weight
- 28889.425 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural molecule activity
- Specific Function
- Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
- Gene Name
- LAMA5
- Uniprot ID
- O15230
- Uniprot Name
- Laminin subunit alpha-5
- Molecular Weight
- 399733.48 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase activity
- Specific Function
- Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
- Gene Name
- F10
- Uniprot ID
- P00742
- Uniprot Name
- Coagulation factor X
- Molecular Weight
- 54731.255 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Protease binding
- Specific Function
- Fibronectins bind cell surfaces and various compounds including collagen, fibrin, heparin, DNA, and actin. Fibronectins are involved in cell adhesion, cell motility, opsonization, wound healing, an...
- Gene Name
- FN1
- Uniprot ID
- P02751
- Uniprot Name
- Fibronectin
- Molecular Weight
- 262623.095 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type endopeptidase inhibitor activity
- Specific Function
- Inhibits urokinase-type plasminogen activator. The monocyte derived PAI-2 is distinct from the endothelial cell-derived PAI-1.
- Gene Name
- SERPINB2
- Uniprot ID
- P05120
- Uniprot Name
- Plasminogen activator inhibitor 2
- Molecular Weight
- 46595.84 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Kringle domain binding
- Specific Function
- Tetranectin binds to plasminogen and to isolated kringle 4. May be involved in the packaging of molecules destined for exocytosis.
- Gene Name
- CLEC3B
- Uniprot ID
- P05452
- Uniprot Name
- Tetranectin
- Molecular Weight
- 22536.665 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural molecule activity
- Specific Function
- Together with KRT19, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.
- Gene Name
- KRT8
- Uniprot ID
- P05787
- Uniprot Name
- Keratin, type II cytoskeletal 8
- Molecular Weight
- 53703.76 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- S100 protein binding
- Specific Function
- Calcium-regulated membrane-binding protein whose affinity for calcium is greatly enhanced by anionic phospholipids. It binds two calcium ions with high affinity. May be involved in heat-stress resp...
- Gene Name
- ANXA2
- Uniprot ID
- P07355
- Uniprot Name
- Annexin A2
- Molecular Weight
- 38603.63 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural molecule activity
- Specific Function
- Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
- Gene Name
- LAMB1
- Uniprot ID
- P07942
- Uniprot Name
- Laminin subunit beta-1
- Molecular Weight
- 198036.545 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Glycosphingolipid binding
- Specific Function
- Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
- Gene Name
- LAMC1
- Uniprot ID
- P11047
- Uniprot Name
- Laminin subunit gamma-1
- Molecular Weight
- 177601.19 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Glycosphingolipid binding
- Specific Function
- Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
- Gene Name
- LAMA1
- Uniprot ID
- P25391
- Uniprot Name
- Laminin subunit alpha-1
- Molecular Weight
- 337080.89 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Calcium-binding chaperone that promotes folding, oligomeric assembly and quality control in the endoplasmic reticulum (ER) via the calreticulin/calnexin cycle. This lectin interacts transiently wit...
- Gene Name
- CALR
- Uniprot ID
- P27797
- Uniprot Name
- Calreticulin
- Molecular Weight
- 48141.2 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Poly(a) rna binding
- Specific Function
- Calcium-binding protein that interacts with newly synthesized glycoproteins in the endoplasmic reticulum. It may act in assisting protein assembly and/or in the retention within the ER of unassembl...
- Gene Name
- CANX
- Uniprot ID
- P27824
- Uniprot Name
- Calnexin
- Molecular Weight
- 67567.695 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Receptor activity
- Specific Function
- Endocytic receptor involved in endocytosis and in phagocytosis of apoptotic cells. Required for early embryonic development. Involved in cellular lipid homeostasis. Involved in the plasma clearance...
- Gene Name
- LRP1
- Uniprot ID
- Q07954
- Uniprot Name
- Prolow-density lipoprotein receptor-related protein 1
- Molecular Weight
- 504601.695 Da
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural molecule activity
- Specific Function
- Binding to cells via a high affinity receptor, laminin is thought to mediate the attachment, migration and organization of cells into tissues during embryonic development by interacting with other ...
- Gene Name
- LAMA3
- Uniprot ID
- Q16787
- Uniprot Name
- Laminin subunit alpha-3
- Molecular Weight
- 366646.12 Da
Drug created at March 19, 2008 16:19 / Updated at February 21, 2021 18:52